Story
UBS Lifts Stoxx 600 Targets on Broadening Earnings Resilience

Summary
UBS has significantly raised its year-end price targets for the pan-European Stoxx 600 index, citing stronger-than-expected corporate earnings that are showing resilience across a widening range of sectors.
UBS has upgraded its forecast for the pan-European Stoxx 600 index, citing corporate earnings that are proving more resilient than previously anticipated. In a note to clients, the Swiss bank raised its 2026 year-end target to 690 from 630 and its 2027 target to 760 from 680.
Rationale for the Upgrade
Strategists Gerry Fowler and Sutanya Chedda attributed the revision to a broadening improvement in the earnings outlook beyond a few select sectors. They highlighted three key changes in their assessment:
- Artificial Intelligence: AI-related earnings upgrades have continued and strengthened.
- Banking Sector: Banks continue to experience positive earnings revisions.
- Defensive Sectors: Large defensive industries, aided by a weaker euro, are no longer a drag on the index.
This combination is now expected to support robust earnings growth of over 10% and justify a higher valuation multiple of around 16 times earnings, according to the bank.
From Narrow Leadership to Broad Strength
AdThe bank's previous targets reflected a market with narrow leadership and concerns over inflation linked to geopolitical conflict. UBS now deems that judgment "too cautious," noting that positive earnings momentum is no longer confined to semiconductor and AI-related companies.
Sectors including luxury, consumer staples, pharmaceuticals, banks, and industrials are now reporting a more stable or improving outlook. This broadening strength makes it "increasingly difficult to find downside risk at the index level," the strategists wrote.
Market Outlook and Caveats
UBS expects market leadership to remain concentrated in AI enablers, banks, and parts of the industrial sector, which collectively account for 40-50% of the index. However, former laggards like luxury, pharma, and select defensives are becoming "investable again" as their earnings expectations stabilize.
Despite the optimistic revision, the strategists clarified this is "not a call for euphoria" but rather "a call for less caution." They noted that Europe's macroeconomic backdrop remains unimpressive by global standards. The upcoming second-quarter earnings season will be a key test to confirm if the recent improvement is durable.